A Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Two Different Intranasal Formulations of MSP-2017 in Healthy Adult Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Etripamil (Primary)
- Indications Arrhythmias; Paroxysmal supraventricular tachycardia
- Focus Adverse reactions
- Sponsors Milestone Pharmaceuticals
- 24 Nov 2014 Results published in a Milestone Pharmaceuticals media release.
- 24 Nov 2014 Status changed from recruiting to completed, according to a Milestone Pharmaceuticals media release.
- 24 Nov 2014 One of the two trial formulations of MSP 2017 has been selected for a phase II proof-of-concept study, according to a Milestone Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History